Nelson Greene, MD
Pulmonary Disease · Salem, VANPI 1801875455
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $27,436 of the $31,315 with a category attached, or 87.6%. It is spread thinly across 50 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,496 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Sanofi$2K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Mallinckrodt Hospital Products Inc.$2K
- plus $17K from 44 others
What the payments were for
- Consulting fees$140%
- Travel & lodging$2,8019%
- Food & beverage$27,43688%
- Education$1,0643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$934
- Olympus Capital Accessories$857
- Olympus EBUS Bronchoscopes$857
- Olympus Respiratory Accessories$857
- TEZSPIRE$763
- BREZTRI$721
- AIRSUPRA$463
- SYMBICORT$442
- BEVESPI AEROSPHERE$243
- DUPIXENT$241
- PURIFIED CORTROPHIN GEL$227
- Da Vinci Surgical System$212
- IMFINZI$150
- TAGRISSO$150
- Monarch Platform$143
- CHARTIS CATHETER$107
- ZEPHYR DELIVERY CATHETER$107
- ZEPHYR ENDOBRONCHIAL VALVE$107
- PULMONX CHARTIS TABLET CONSOLE$107
- BREZTRI AEROSPHERE$106
How this compares
$31,315 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 38 | $479,995 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 392 | $319,199 |
| OfevNintedanib Esylate | 27 | $295,411 |
| Tyvaso DpiTreprostinil | 12 | $281,109 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $174,785 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $143,956 |
| TezspireTezepelumab-Ekko | 33 | $134,027 |
| Breo ElliptaFluticasone/Vilanterol | 160 | $77,828 |
| Dupixent PenDupilumab | 20 | $76,459 |
| FasenraBenralizumab | 12 | $73,819 |
| NucalaMepolizumab | 17 | $61,743 |
| Spiriva RespimatTiotropium Bromide | 64 | $45,188 |
| EliquisApixaban | 71 | $44,781 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $41,235 |
| Ambrisentan | 12 | $33,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $2,776 | $500,531650 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,849 | $479,99538 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,850 | $397,425179 claims |
| AstraZenecaTezspire, Fasenra, Symbicort, Breztri Aerosphere | $4,456 | $278,954176 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $736 | $174,78514 claims |
| PfizerEliquis | $55 | $44,78171 claims |
| Johnson & JohnsonXarelto | $670 | $6,56812 claims |
| MerckDulera | $205 | $6,06416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Salem
- James WittenSalem$119K
- David KilleenSalem$47K
- Douglas DorseySalem$18K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.